Can ParC Ser83Ile status predict fluoroquinolone efficacy in Mycoplasma genitalium infection?

Lancet Infect Dis. 2022 Sep;22(9):1273-1274. doi: 10.1016/S1473-3099(22)00450-9.

Authors

Xinying Leng¹, Huachun Zou², Kechun Zhang³, Yaqi Chen³, Wujian Ke⁴

Affiliations

¹ Department of Sexually Transmitted Diseases, Dermatology Hospital, Southern Medical University, Guangzhou, 510091, China.
² School of Public Health, Sun Yat-Sen University, Shenzhen, Guangdong, China.
³ Longhua Center for Disease Control and Prevention, Shenzhen, Guangdong, China.
⁴ Department of Sexually Transmitted Diseases, Dermatology Hospital, Southern Medical University, Guangzhou, 510091, China. Electronic address: kewujianstauch@163.com.

PMID: 36029777
DOI: 10.1016/S1473-3099(22)00450-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Bacterial Agents
DNA Gyrase
Drug Resistance, Bacterial
Fluoroquinolones
Humans
Macrolides
Mutation
Mycoplasma Infections*
Mycoplasma genitalium*

Substances

Anti-Bacterial Agents
Fluoroquinolones
Macrolides
DNA Gyrase